Axonics (NASDAQ:AXNX) quickly edged higher by 0.8% after a Nasdaq delisting notice for its planned sale to Boston Scientific ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Strong sales of a medical device to treat atrial fibrillation helped lift Boston Scientific’s top line last quarter, but an unexpected pause in an important clinical trial to expand the use of ...

The Celtics shocked the wider world when the team's majority owners -- the Grousbecks -- announced they were selling their ...

We recently compiled a list of the 8 Hot Growth Stocks To Buy According to Hedge Funds. In this article, we are going to take ...

Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products company reported ...

On an adjusted basis, Boston Scientific reported earnings of 63 cents a share, above the FactSet consensus of 59 cents a share. Sales were $4.209 billion, up 19.4% from $3.527 billion in the prior ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

As Boston Scientific’s pulsed field ablation business continues to grow, the medtech aims to nourish the program with the ...

Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Boston Scientific posted third-quarter net income ahead of Wall Street estimates and jacked up its forecast for 2024 revenue growth as increased medical activity lifts sales of surgical equipment ...